NCT00005951View on ClinicalTrials.gov

Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

August 31, 2000

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

irinotecan hydrochloride

DRUG

temozolomide

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER

NCT00005951 - Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma | Biotech Hunter | Biotech Hunter